<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644315</url>
  </required_header>
  <id_info>
    <org_study_id>BO41929</org_study_id>
    <nct_id>NCT04644315</nct_id>
  </id_info>
  <brief_title>A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors</brief_title>
  <acronym>ALpha-T</acronym>
  <official_title>A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic&#xD;
      Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR) as Determined by the Investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)</measure>
    <time_frame>From 28 days after initial response up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed ORR as Determined by Blinded Independent Center Review (BICR) per RECIST v1.1</measure>
    <time_frame>From 28 days after initial response up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by both the Investigator and by BICR per RECIST v1.1</measure>
    <time_frame>From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by both the Investigator and by BICR per RECIST v1.1</measure>
    <time_frame>From first dose of alectinib to disease progression or death from any cause, whichever occurs first (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System (CNS) ORR by BICR per RECIST v1.1</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS DOR by BICR per RECIST v1.1</measure>
    <time_frame>From the first observation of CNS response to the first observation of CNS progression or death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose of study drug to death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Alectinib</measure>
    <time_frame>At pre-defined intervals from baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per Response Assessment in Neuro-Oncology (RANO) Criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per RANO Criteria</measure>
    <time_frame>From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per RANO Criteria</measure>
    <time_frame>From first dose of alectinib to disease progression or death from any cause, whichever occurs first (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Participants with Primary CNS Tumors</measure>
    <time_frame>From the first dose of study drug to death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Melanoma</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Sarcoma</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Brain Neoplasms</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Salivary Gland Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Thyroid Cancer, Papillary</condition>
  <condition>Lymphoma, Large-Cell, Anaplastic</condition>
  <condition>Neoplasms by Site</condition>
  <condition>Respiratory Tract Neoplasms</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Bronchial Neoplasms</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Colonic Diseases</condition>
  <condition>Intestinal Diseases</condition>
  <condition>Central Nervous System</condition>
  <arm_group>
    <arm_group_label>ALK-positive Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.</description>
    <arm_group_label>ALK-positive Solid Tumors</arm_group_label>
    <other_name>Alecensa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed ALK-positive locally-advanced or metastatic solid tumor&#xD;
             excluding lung cancer&#xD;
&#xD;
          -  ALK-positive tumor as per Foundation Medicine, Inc (FMI) next-generation sequencing&#xD;
             (NGS) (NGS F1CDx, F1LCDx, or F1HEME) or per local accredited laboratory using&#xD;
             validated NGS testing of tumor tissue or peripheral blood&#xD;
&#xD;
          -  No alternative effective standard therapy available, or standard therapy considered&#xD;
             unsuitable or intolerable to the participant&#xD;
&#xD;
          -  Other cancer therapies are allowed, including investigational drugs, if any&#xD;
             treatment-related toxicities (excluding alopecia) have resolved to grade &lt;/= 1 or to&#xD;
             laboratory values as defined by the protocol&#xD;
&#xD;
          -  Measurable disease at baseline as assessed by the Investigator per RECIST v1.1 or RANO&#xD;
             criteria (for participants with primary CNS tumors)&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Adequate hemataologic, hepatic, and renal function&#xD;
&#xD;
          -  Participants with primary central nervous system (CNS) tumors are available&#xD;
&#xD;
          -  Participants with brain or leptomeningeal metastasis are allowed in the study if&#xD;
             asymptomatic and if they meet additional criteria as defined by the protocol&#xD;
&#xD;
          -  Willingness to comply with study procedures&#xD;
&#xD;
          -  Willingness to comply with home-base approach and visits by Mobile Nurses&#xD;
&#xD;
          -  Ability to swallow alectinib capsules intact&#xD;
&#xD;
          -  Women of childbearing potential must test negative for pregnancy at screening and&#xD;
             prior to the first dose of study drug&#xD;
&#xD;
          -  Women of childbearing potential must agree to remain abstinent or use contraceptive&#xD;
             methods as defined by the protocol and refrain from donating eggs during the treatment&#xD;
             period and for at least 90 days after the last dose of alectinib&#xD;
&#xD;
          -  Men must agree to remain abstinent or use contraceptive methods as defined by the&#xD;
             protocol and refrain from donating sperm during the treatment period and for at least&#xD;
             90 days after the last dose of alectinib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the final dose of alectinib&#xD;
&#xD;
          -  Lung Cancer&#xD;
&#xD;
          -  Patients with one of the following ALK point mutations: I1171X, G1202R, V1180L&#xD;
&#xD;
          -  Prior therapy with an ALK inhibitor&#xD;
&#xD;
          -  Liver disease as described in the protocol&#xD;
&#xD;
          -  Known HIV, hepatitis B, or hepatitis C (HCV) infection&#xD;
&#xD;
          -  Patients with symptomatic bradycardia&#xD;
&#xD;
          -  Patients with symptomatic or unstable brain metastasis; patients with primary CNS&#xD;
             tumors are allowed&#xD;
&#xD;
          -  Malabsorption syndrome or any other condition that would interfere with enteral&#xD;
             absorption&#xD;
&#xD;
          -  Incomplete recovery from any surgery prior to treatment&#xD;
&#xD;
          -  Any other malignancies within 5 years prior to enrollment, except for those described&#xD;
             in the protocol&#xD;
&#xD;
          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             Investigator's judgment, precludes the patient's safe participation in and completion&#xD;
             of the study&#xD;
&#xD;
          -  History of hypersensitivity to any of the ingredients in the alectinib drug&#xD;
             formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO41929 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Science 37, Inc</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Science 37, Inc</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Science 37, Inc</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Homebased Telemedicine</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>agnostic</keyword>
  <keyword>ALK+</keyword>
  <keyword>Alk-positive</keyword>
  <keyword>ALK positive</keyword>
  <keyword>ALK mutation</keyword>
  <keyword>GI</keyword>
  <keyword>breast</keyword>
  <keyword>sarcoma</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>female reproductive</keyword>
  <keyword>ALK</keyword>
  <keyword>ALK fusions</keyword>
  <keyword>ALK gene rearrangements</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>entrectinib</keyword>
  <keyword>basket study</keyword>
  <keyword>salivary gland cancers</keyword>
  <keyword>primary brain tumors</keyword>
  <keyword>melanoma</keyword>
  <keyword>sarcomas</keyword>
  <keyword>papillary thyroid cancer</keyword>
  <keyword>renal cell cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>head &amp; neck cancers</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>anaplastic lymphoma kinase positive</keyword>
  <keyword>solid tumors</keyword>
  <keyword>ALK+ solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Respiratory Tract Neoplasms</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

